Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ral GTPase activating protein non-catalytic subunit beta (RALGAPB)
- Target
- RALGAPB
- Molecular classification
- Regulatory subunit of a protein complex, GTPase-activating protein complex (non-catalytic subunit), Other (does not fit classical receptor, enzyme, ion channel, or transporter)
01
Overview
Ral GTPase activating protein non-catalytic subunit beta (RALGAPB) is a protein coding gene that encodes the non-catalytic regulatory subunit of the RalGAP complex, which acts as a GTPase-activating complex for Ras-like small GTPases RALA and RALB. The RalGAP complex consists of two types of subunits: the catalytic alpha subunit and the non-catalytic beta subunit (RALGAPB), forming heterodimeric complexes (RalGAP1, RalGAP2). RALGAPB contributes to the regulation of Ral signaling pathways, which are important in vesicular trafficking, exocyst localization, and cellular signal transduction. Dysregulation of the Ral pathway has been linked to oncogenic transformation and various developmental diseases, suggesting a potential research interest in cancer and other disorders of cellular signaling
- Other names
- RalGAPbetaKIAA1219DKFZp781M2411p170Ral GTPase-activating protein subunit betaRal GTPase activating protein, beta subunit (non-catalytic)
02
Mechanism of action
Not applicable for clinically approved drugs, but mechanistic research involves inhibition or modulation of the RalGAP complex's regulation of RALA/RALB signaling, which may impact tumor suppression or vesicular trafficking
03
Biological functions
Signal transductionGTPase activation (via interaction with RALA and RALB GTPases)Protein heterodimerizationRegulation of exocyst localizationRegulation of protein localization
04
Disease associations
Cancer (associated with tumor suppressor functions and vesicular trafficking dysregulation)TubulinopathySeptooptic dysplasia
05
Safety considerations
Safety concerns for targeting RALGAPB are unknown, as no drugs are clinically advanced; perturbing Ral GTPase signaling could hypothetically affect basic cellular processes and pose risks
06
Interacting drugs
No clinically approved drugs directly targeting RALGAPB have been reported; molecular targeting is under basic research investigation
07
Biomarkers
No established clinical biomarkers related to RALGAPB for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Ral GTPase activating protein non-catalytic subunit beta (RALGAPB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ral GTPase activating protein non-catalytic subunit beta (RALGAPB).